Tag: Car t cell therapy

Approximately 40% of non-Hodgkin lymphoma patients do not respond to initial chemotherapy, highlighting the need for advanced treatments. **Is Breyanzi an immunotherapy?** Yes, it is—specifically, it is an innovative type of CAR T-cell therapy that uses a patient's own modified immune cells to attack cancer.

First approved by the FDA in February 2021, Breyanzi (lisocabtagene maraleucel) is a revolutionary and personalized form of cancer treatment. So, what is the generic name for Breyanzi? It is lisocabtagene maraleucel, a highly specialized and individualized cellular immunotherapy. This therapy is developed for each patient using their own genetically modified immune cells to fight specific blood cancers.

In late 2024 and early 2025, advanced cell therapy modalities like CAR-T therapy gained significant interest for autoimmune diseases like lupus. The emerging landscape provides new hope for those wondering, **What is the new treatment for lupus 2025?**, as a range of innovative therapies progress through clinical trials and regulatory review.

Unlike traditional chemotherapy, Yescarta is a personalized medicine derived from a patient's own T-cells. The intricate process of **how is Yescarta administered** involves multiple stages, beginning with cell collection and culminating in a carefully monitored, one-time intravenous infusion at a certified facility.

In 2023, the U.S. spent $99 billion on anticancer therapies, a figure projected to hit $180 billion by 2028 [1.9.3]. Answering 'What is the most expensive chemotherapy drug?' now involves looking beyond traditional chemotherapy to advanced, multi-million dollar gene therapies.